61 VCs and 5 funds investing in Medical Devices
Partner
Khosla Ventures
Check: No personal check range is published. Khosla's Seed Fund supports science and business-model experiments, historically often with roughly $1M–$2M according to a 2020 firm interview, while its Main Fund covers early through later stages. These are firm-level references, not Alex's authority.
Alex invests where computation, biology, and healthcare converge. His scientific and clinical background supports a systems view of biomarker discovery, therapeutics, diagnostics, personalized medicine, neurotechnology, connected devices, and AI-enabled care. He favors important health outcomes and technologies that can automate expensive or inconsistent processes, increase access, and create reproducible, lower-cost care—not science detached from delivery and economics.
Investor
BoxGroup
Check: No reliable Arielle-specific check size is public. BoxGroup describes itself as an earliest-stage investor, but founders should confirm current round fit and allocation directly rather than relying on third-party range estimates.
Arielle invests within BoxGroup's broad earliest-stage mandate. Her differentiated documented context is technical and translational: Harvard bioengineering research, founding a postpartum medical-device project, product work in fertility AI and neuromodulation, mechanical engineering at a bioelectronic-medicine startup, and consulting at BCG. This supports a credible ability to evaluate user need, clinical workflow, product design, manufacturing, regulatory planning and commercialization in technical health businesses. It does not establish an exclusive healthcare mandate or a personally published investment thesis.
Partner Emeritus
Big Pi Ventures
Check: No current personal check range: Aristos is Partner Emeritus and an official 2025 biography says he is not involved with Big Pi's later funds. Big Pi's current platform range is €0.5M–€30M across funds, but should not be attributed to him.
Aristos' historical investment lens combines strong technology, team, and market position with realistic commercialization targets. He favors research-based ventures that can bridge academia and industry, secure early adopters beyond a small home market, and use seed or Series A capital to build enough traction for international follow-on funding. His long private-equity career also brings attention to governance, business fundamentals, and social or economic impact.
General Partner
S3 Ventures
Check: $500K-$15M+ initial check range published by S3 Ventures; no person-specific range is disclosed.
Eric Engineer is part of S3 Ventures's current team. No narrower person-specific mandate is published, so this profile uses the firm's official strategy: Lead Seed, Series A, and Series B rounds in business software and healthcare technology using patient single-LP capital and hands-on operating resources.
General Partner
S3 Ventures
Check: $500K-$15M+ initial check range published by S3 Ventures; no person-specific range is disclosed.
Aaron Perman is part of S3 Ventures's current team. No narrower person-specific mandate is published, so this profile uses the firm's official strategy: Lead Seed, Series A, and Series B rounds in business software and healthcare technology using patient single-LP capital and hands-on operating resources.
Principal
S3 Ventures
Check: $500K-$15M+ initial check range published by S3 Ventures; no person-specific range is disclosed.
Joe Curry is part of S3 Ventures's current team. No narrower person-specific mandate is published, so this profile uses the firm's official strategy: Lead Seed, Series A, and Series B rounds in business software and healthcare technology using patient single-LP capital and hands-on operating resources.
Vice President
S3 Ventures
Check: $500K-$15M+ initial check range published by S3 Ventures; no person-specific range is disclosed.
Nicole Bentz is part of S3 Ventures's current team. No narrower person-specific mandate is published, so this profile uses the firm's official strategy: Lead Seed, Series A, and Series B rounds in business software and healthcare technology using patient single-LP capital and hands-on operating resources.
Associate
S3 Ventures
Check: $500K-$15M+ initial check range published by S3 Ventures; no person-specific range is disclosed.
Anthony Marfisi is part of S3 Ventures's current team. No narrower person-specific mandate is published, so this profile uses the firm's official strategy: Lead Seed, Series A, and Series B rounds in business software and healthcare technology using patient single-LP capital and hands-on operating resources.
Associate
S3 Ventures
Check: $500K-$15M+ initial check range published by S3 Ventures; no person-specific range is disclosed.
Kevin Haley is part of S3 Ventures's current team. No narrower person-specific mandate is published, so this profile uses the firm's official strategy: Lead Seed, Series A, and Series B rounds in business software and healthcare technology using patient single-LP capital and hands-on operating resources.
Senior Associate
S3 Ventures
Check: $500K-$15M+ initial check range published by S3 Ventures; no person-specific range is disclosed.
Will Omberg is part of S3 Ventures's current team. No narrower person-specific mandate is published, so this profile uses the firm's official strategy: Lead Seed, Series A, and Series B rounds in business software and healthcare technology using patient single-LP capital and hands-on operating resources.
Director of Platform & Network
S3 Ventures
Check: $500K-$15M+ initial check range published by S3 Ventures; no person-specific range is disclosed.
Kathryn Deebel is part of S3 Ventures's current team. No narrower person-specific mandate is published, so this profile uses the firm's official strategy: Lead Seed, Series A, and Series B rounds in business software and healthcare technology using patient single-LP capital and hands-on operating resources.
Controller
S3 Ventures
Check: $500K-$15M+ initial check range published by S3 Ventures; no person-specific range is disclosed.
Shelley Graves is part of S3 Ventures's current team. No narrower person-specific mandate is published, so this profile uses the firm's official strategy: Lead Seed, Series A, and Series B rounds in business software and healthcare technology using patient single-LP capital and hands-on operating resources.
General Partner
Boomerang Ventures
Check: Boomerang Ventures does not publish a standard current check-size range on its official site.
Alex Shandiz invests or supports investments through Boomerang Ventures's published strategy: Build and invest in connected-health companies improving care quality, access, delivery, efficiency and patient experience, with particular attention to Midwest opportunities.
Venture Partner
Boomerang Ventures
Check: Boomerang Ventures does not publish a standard current check-size range on its official site.
Ariel MacTavish invests or supports investments through Boomerang Ventures's published strategy: Build and invest in connected-health companies improving care quality, access, delivery, efficiency and patient experience, with particular attention to Midwest opportunities.
Partner and Chief Innovation Officer
Boomerang Ventures
Check: Boomerang Ventures does not publish a standard current check-size range on its official site.
Audrey Beckman invests or supports investments through Boomerang Ventures's published strategy: Build and invest in connected-health companies improving care quality, access, delivery, efficiency and patient experience, with particular attention to Midwest opportunities.
Studio Director
Boomerang Ventures
Check: Boomerang Ventures does not publish a standard current check-size range on its official site.
Dick Aderman is listed in a Studio Director capacity at Boomerang Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves that role distinction and uses the firm's mandate only as shared context.
Founder and Managing Partner
Boomerang Ventures
Check: Boomerang Ventures does not publish a standard current check-size range on its official site.
Oscar Moralez invests or supports investments through Boomerang Ventures's published strategy: Build and invest in connected-health companies improving care quality, access, delivery, efficiency and patient experience, with particular attention to Midwest opportunities.
Controller and HR Lead
Boomerang Ventures
Check: Boomerang Ventures does not publish a standard current check-size range on its official site.
Todd R. Lugar is listed in a Controller and HR Lead capacity at Boomerang Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves that role distinction and uses the firm's mandate only as shared context.
Partner and Chief Financial Officer
Boomerang Ventures
Check: Boomerang Ventures does not publish a standard current check-size range on its official site.
Tony Petrucciani is listed in a Partner and Chief Financial Officer capacity at Boomerang Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves that role distinction and uses the firm's mandate only as shared context.
Co-Founder and Partner
Mutual Capital Partners
Check: Mutual Capital Partners does not publish a standard current check-size range on its official site.
Bill Trainor invests or supports investments through Mutual Capital Partners's published strategy: Partner with healthcare IT and medical-device companies outside major technology centers that have strong teams, reference customers, meaningful revenue and attractive margins.
Co-Founder and Partner
Mutual Capital Partners
Check: Mutual Capital Partners does not publish a standard current check-size range on its official site.
Wayne Wallace invests or supports investments through Mutual Capital Partners's published strategy: Partner with healthcare IT and medical-device companies outside major technology centers that have strong teams, reference customers, meaningful revenue and attractive margins.
Project Leader
Boomerang Ventures
Check: Boomerang Ventures does not publish a standard current check-size range on its official site.
Ally Thill is listed in a Project Leader capacity at Boomerang Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves that role distinction and uses the firm's mandate only as shared context.
Venture Partner
Boomerang Ventures
Check: Boomerang Ventures does not publish a standard current check-size range on its official site.
Dan Clark invests or supports investments through Boomerang Ventures's published strategy: Build and invest in connected-health companies improving care quality, access, delivery, efficiency and patient experience, with particular attention to Midwest opportunities.
Partner
Boomerang Ventures
Check: Boomerang Ventures does not publish a standard current check-size range on its official site.
David Helmer invests or supports investments through Boomerang Ventures's published strategy: Build and invest in connected-health companies improving care quality, access, delivery, efficiency and patient experience, with particular attention to Midwest opportunities.
Partner and Chief Medical Officer
Boomerang Ventures
Check: Boomerang Ventures does not publish a standard current check-size range on its official site.
Eric Beier invests or supports investments through Boomerang Ventures's published strategy: Build and invest in connected-health companies improving care quality, access, delivery, efficiency and patient experience, with particular attention to Midwest opportunities.
Associate
Boomerang Ventures
Check: Boomerang Ventures does not publish a standard current check-size range on its official site.
Tejas Vijh invests or supports investments through Boomerang Ventures's published strategy: Build and invest in connected-health companies improving care quality, access, delivery, efficiency and patient experience, with particular attention to Midwest opportunities.
Principal
Mutual Capital Partners
Check: Mutual Capital Partners does not publish a standard current check-size range on its official site.
Liz Todia Zambory invests or supports investments through Mutual Capital Partners's published strategy: Partner with healthcare IT and medical-device companies outside major technology centers that have strong teams, reference customers, meaningful revenue and attractive margins.
Senior Associate
Mutual Capital Partners
Check: Mutual Capital Partners does not publish a standard current check-size range on its official site.
Will Brune invests or supports investments through Mutual Capital Partners's published strategy: Partner with healthcare IT and medical-device companies outside major technology centers that have strong teams, reference customers, meaningful revenue and attractive margins.
Managing Partner
RC Capital
Check: RC Capital does not publish a standard check-size range on its current official website.
Daniel Fleming contributes to RC Capital's published strategy: Build high-potential healthcare companies that improve care delivery, patient experience and outcomes across devices, services and healthcare IT.
Managing Partner
RC Capital
Check: RC Capital does not publish a standard check-size range on its current official website.
J. Carter McNabb contributes to RC Capital's published strategy: Build high-potential healthcare companies that improve care delivery, patient experience and outcomes across devices, services and healthcare IT.
Managing Partner
RC Capital
Check: RC Capital does not publish a standard check-size range on its current official website.
Robert Heimann contributes to RC Capital's published strategy: Build high-potential healthcare companies that improve care delivery, patient experience and outcomes across devices, services and healthcare IT.
Managing Partner
RC Capital
Check: RC Capital does not publish a standard check-size range on its current official website.
Rurik “Rik” Vandevenne contributes to RC Capital's published strategy: Build high-potential healthcare companies that improve care delivery, patient experience and outcomes across devices, services and healthcare IT.
Partner
RC Capital
Check: RC Capital does not publish a standard check-size range on its current official website.
Patrick Dunnigan contributes to RC Capital's published strategy: Build high-potential healthcare companies that improve care delivery, patient experience and outcomes across devices, services and healthcare IT.
CFO
RC Capital
Check: RC Capital does not publish a standard check-size range on its current official website.
Adrienne Vannarsdall contributes to RC Capital's published strategy: Build high-potential healthcare companies that improve care delivery, patient experience and outcomes across devices, services and healthcare IT.
Principal
RC Capital
Check: RC Capital does not publish a standard check-size range on its current official website.
Parag Rathi contributes to RC Capital's published strategy: Build high-potential healthcare companies that improve care delivery, patient experience and outcomes across devices, services and healthcare IT.
Principal
RC Capital
Check: RC Capital does not publish a standard check-size range on its current official website.
Vitaly Goldfeder contributes to RC Capital's published strategy: Build high-potential healthcare companies that improve care delivery, patient experience and outcomes across devices, services and healthcare IT.
Principal, Investor Relations & Operations
RC Capital
Check: RC Capital does not publish a standard check-size range on its current official website.
Britney Hamberg contributes to RC Capital's published strategy: Build high-potential healthcare companies that improve care delivery, patient experience and outcomes across devices, services and healthcare IT.
Controller
RC Capital
Check: RC Capital does not publish a standard check-size range on its current official website.
Dana Tanenbaum contributes to RC Capital's published strategy: Build high-potential healthcare companies that improve care delivery, patient experience and outcomes across devices, services and healthcare IT.
Vice President
RC Capital
Check: RC Capital does not publish a standard check-size range on its current official website.
Paul Axelrod contributes to RC Capital's published strategy: Build high-potential healthcare companies that improve care delivery, patient experience and outcomes across devices, services and healthcare IT.
Vice President
RC Capital
Check: RC Capital does not publish a standard check-size range on its current official website.
Scott Steever contributes to RC Capital's published strategy: Build high-potential healthcare companies that improve care delivery, patient experience and outcomes across devices, services and healthcare IT.
Vice President
RC Capital
Check: RC Capital does not publish a standard check-size range on its current official website.
Ryan Moeller contributes to RC Capital's published strategy: Build high-potential healthcare companies that improve care delivery, patient experience and outcomes across devices, services and healthcare IT.
Senior Associate
RC Capital
Check: RC Capital does not publish a standard check-size range on its current official website.
Marcus Fields contributes to RC Capital's published strategy: Build high-potential healthcare companies that improve care delivery, patient experience and outcomes across devices, services and healthcare IT.
Analyst, Investor Relations
RC Capital
Check: RC Capital does not publish a standard check-size range on its current official website.
Saloni Rai contributes to RC Capital's published strategy: Build high-potential healthcare companies that improve care delivery, patient experience and outcomes across devices, services and healthcare IT.
Analyst, Investments
RC Capital
Check: RC Capital does not publish a standard check-size range on its current official website.
Kushal Modi contributes to RC Capital's published strategy: Build high-potential healthcare companies that improve care delivery, patient experience and outcomes across devices, services and healthcare IT.
Analyst, Finance
RC Capital
Check: RC Capital does not publish a standard check-size range on its current official website.
Britney Byrd contributes to RC Capital's published strategy: Build high-potential healthcare companies that improve care delivery, patient experience and outcomes across devices, services and healthcare IT.
Manager of Administration
RC Capital
Check: RC Capital does not publish a standard check-size range on its current official website.
Kaity Lynch contributes to RC Capital's published strategy: Build high-potential healthcare companies that improve care delivery, patient experience and outcomes across devices, services and healthcare IT.
Managing Partner
Clarevia
Check: Clarevia does not publish a standard current check-size range on its official site.
Jim Adox invests or supports investments through Clarevia's published strategy: Back visionary healthcare entrepreneurs and breakthrough ideas that can improve patient lives, from therapeutic and device innovation to new care solutions.
Partner
Clarevia
Check: Clarevia does not publish a standard current check-size range on its official site.
Scott Button invests or supports investments through Clarevia's published strategy: Back visionary healthcare entrepreneurs and breakthrough ideas that can improve patient lives, from therapeutic and device innovation to new care solutions.
Partner
Clarevia
Check: Clarevia does not publish a standard current check-size range on its official site.
Paul Weiss invests or supports investments through Clarevia's published strategy: Back visionary healthcare entrepreneurs and breakthrough ideas that can improve patient lives, from therapeutic and device innovation to new care solutions.
Partner and Chief Financial Officer
Clarevia
Check: Clarevia does not publish a standard current check-size range on its official site.
David Arnstein is listed in a Partner and Chief Financial Officer capacity at Clarevia. No person-specific investment thesis is published for this role; the firm's mandate is included only as shared context.
Partner
Clarevia
Check: Clarevia does not publish a standard current check-size range on its official site.
John Neis invests or supports investments through Clarevia's published strategy: Back visionary healthcare entrepreneurs and breakthrough ideas that can improve patient lives, from therapeutic and device innovation to new care solutions.
Chief Medical and Scientific Officer
Clarevia
Check: Clarevia does not publish a standard current check-size range on its official site.
Joe Amaral, MD is listed in a Chief Medical and Scientific Officer capacity at Clarevia. No person-specific investment thesis is published for this role; the firm's mandate is included only as shared context.
Principal
Clarevia
Check: Clarevia does not publish a standard current check-size range on its official site.
Jenni Le invests or supports investments through Clarevia's published strategy: Back visionary healthcare entrepreneurs and breakthrough ideas that can improve patient lives, from therapeutic and device innovation to new care solutions.
Venture Partner
Clarevia
Check: Clarevia does not publish a standard current check-size range on its official site.
Margaret Kaczor Andrew invests or supports investments through Clarevia's published strategy: Back visionary healthcare entrepreneurs and breakthrough ideas that can improve patient lives, from therapeutic and device innovation to new care solutions.
Executive in Residence
Clarevia
Check: Clarevia does not publish a standard current check-size range on its official site.
Cheryl R. Blanchard, PhD invests or supports investments through Clarevia's published strategy: Back visionary healthcare entrepreneurs and breakthrough ideas that can improve patient lives, from therapeutic and device innovation to new care solutions.
Venture Partner
Clarevia
Check: Clarevia does not publish a standard current check-size range on its official site.
Shelly Lanning invests or supports investments through Clarevia's published strategy: Back visionary healthcare entrepreneurs and breakthrough ideas that can improve patient lives, from therapeutic and device innovation to new care solutions.
Controller
Clarevia
Check: Clarevia does not publish a standard current check-size range on its official site.
Becky Hoerman is listed in a Controller capacity at Clarevia. No person-specific investment thesis is published for this role; the firm's mandate is included only as shared context.
Office Manager
Clarevia
Check: Clarevia does not publish a standard current check-size range on its official site.
Linda Olson is listed in a Office Manager capacity at Clarevia. No person-specific investment thesis is published for this role; the firm's mandate is included only as shared context.
Managing Director
S3 Ventures
Check: $500K-$15M+ initial check range published by S3 Ventures; no person-specific range is disclosed.
Brian R. Smith is part of S3 Ventures's current team. No narrower person-specific mandate is published, so this profile uses the firm's official strategy: Lead Seed, Series A, and Series B rounds in business software and healthcare technology using patient single-LP capital and hands-on operating resources.
Managing Director
S3 Ventures
Check: $500K-$15M+ initial check range published by S3 Ventures; no person-specific range is disclosed.
Charlie Plauche is part of S3 Ventures's current team. No narrower person-specific mandate is published, so this profile uses the firm's official strategy: Lead Seed, Series A, and Series B rounds in business software and healthcare technology using patient single-LP capital and hands-on operating resources.
Partner
Khosla Ventures
Check: No reliable current personal check range was found. Khosla Ventures invests across company stages and is known for both early technical risk and later follow-on support, but founders should ask Jun about the applicable vehicle, initial ownership, reserves and decision process rather than relying on marketplace estimates.
Jun backs long-horizon technologies at the intersection of biology, healthcare and frontier engineering. His medical training, decade of bench and clinical research, digital-health operating work and company-formation experience support a first-principles lens: take technically difficult risks where a validated breakthrough could materially improve health, then confront clinical evidence, affordability, access, regulation and real-world adoption early.